Clinical trial
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
NCT00046527 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00046527 |
|---|---|
| Title | Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer |
| Official title | A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007(a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients With Metastatic Breast Cancer |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 460 |
| Start date | Jun 1, 2001 |
| First posted | Oct 3, 2002 |
| Last update posted | Jul 13, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: